Targeting human TLRs to combat COVID-19: A solution?
作者信息
Patra Ritwik, Chandra Das Nabarun, Mukherjee Suprabhat
机构信息
Integrative Biochemistry & Immunology Laboratory, Department of Animal Science, Kazi Nazrul University, Asansol, West Bengal, India.
出版信息
J Med Virol. 2021 Feb;93(2):615-617. doi: 10.1002/jmv.26387. Epub 2020 Aug 13.
Abstract
摘要
相似文献
1
Targeting human TLRs to combat COVID-19: A solution?靶向人类Toll样受体以对抗新冠病毒：一种解决方案？
J Med Virol. 2021 Feb;93(2):615-617. doi: 10.1002/jmv.26387. Epub 2020 Aug 13.
2
The outcome of COVID-19 in patients with hematological malignancy.血液系统恶性肿瘤患者的新冠病毒病结局
J Med Virol. 2021 Mar;93(3):1229. doi: 10.1002/jmv.26576. Epub 2020 Oct 10.
3
Concerns regarding calculation of fatality rate of Chinese samples in COVID-19 meta-analysis.关于新冠病毒荟萃分析中中国样本死亡率计算的担忧。
J Med Virol. 2020 Jul;92(7):710. doi: 10.1002/jmv.25799. Epub 2020 Apr 10.
4
Cofilin, an intracellular marker for HIV-associated CD4 T-cell motility dysregulation, shed light on the mechanisms of incomplete immune reconstitution in the patients with HIV.丝切蛋白是一种与HIV相关的CD4 T细胞运动失调的细胞内标志物，它为HIV患者免疫重建不完全的机制提供了线索。
J Med Virol. 2020 Jan;92(1):1-3. doi: 10.1002/jmv.25577. Epub 2019 Sep 9.
5
Cofilin hyperactivation in HIV infection and targeting the cofilin pathway using an anti-αβ integrin antibody.HIV 感染中的丝切蛋白 hyperactivation 及使用抗 αβ 整合素抗体靶向丝切蛋白途径。
Sci Adv. 2019 Jan 9;5(1):eaat7911. doi: 10.1126/sciadv.aat7911. eCollection 2019 Jan.
6
Divergent SARS-CoV-2-specific T- and B-cell responses in severe but not mild COVID-19 patients.在重症 COVID-19 患者中而非轻症 COVID-19 患者中存在不同的 SARS-CoV-2 特异性 T 细胞和 B 细胞反应。
Eur J Immunol. 2020 Dec;50(12):1998-2012. doi: 10.1002/eji.202048908. Epub 2020 Nov 16.
7
Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses.急性严重急性呼吸综合征冠状病毒 2 感染损害树突状细胞和 T 细胞应答。
Immunity. 2020 Oct 13;53(4):864-877.e5. doi: 10.1016/j.immuni.2020.07.026. Epub 2020 Aug 4.
8
Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells.胸腺素 α1 通过恢复淋巴细胞减少症和逆转耗竭 T 细胞来降低严重 COVID-19 的死亡率。
Clin Infect Dis. 2020 Nov 19;71(16):2150-2157. doi: 10.1093/cid/ciaa630.
9
The laboratory tests and host immunity of COVID-19 patients with different severity of illness.不同疾病严重程度的 COVID-19 患者的实验室检测和宿主免疫。
JCI Insight. 2020 May 21;5(10):137799. doi: 10.1172/jci.insight.137799.
10
In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs.基于 SARS-CoV-2 刺突糖蛋白与 ACE-2 受体同源物和人类 TLR 相互作用的比较特征的计算机研究。
J Med Virol. 2020 Oct;92(10):2105-2113. doi: 10.1002/jmv.25987. Epub 2020 May 17.
引用本文的文献
1
Preliminary results and a theoretical perspective of co‑treatment using a miR‑93‑5p mimic and aged garlic extract to inhibit the expression of the pro‑inflammatory interleukin‑8 gene.使用miR-93-5p模拟物和 aged garlic extract 联合治疗抑制促炎白细胞介素-8基因表达的初步结果及理论观点
Exp Ther Med. 2025 Feb 25;29(4):85. doi: 10.3892/etm.2025.12835. eCollection 2025 Apr.
2
Immunity and Coagulation in COVID-19.新型冠状病毒肺炎中的免疫与凝血。
Int J Mol Sci. 2024 Oct 19;25(20):11267. doi: 10.3390/ijms252011267.
3
In Silico Design of a Trans-Amplifying RNA-Based Vaccine against SARS-CoV-2 Structural Proteins.基于跨扩增RNA的抗SARS-CoV-2结构蛋白疫苗的计算机模拟设计
Adv Virol. 2024 Sep 30;2024:3418062. doi: 10.1155/2024/3418062. eCollection 2024.
4
Aggravating mechanisms from COVID-19.COVID-19 的加重机制。
Virol J. 2024 Sep 27;21(1):228. doi: 10.1186/s12985-024-02506-8.
5
Insight into genomic organization of pathogenic coronaviruses, SARS-CoV-2: Implication for emergence of new variants, laboratory diagnosis and treatment options.深入了解致病性冠状病毒SARS-CoV-2的基因组组织：对新变种出现、实验室诊断和治疗选择的启示
Front Mol Med. 2022 Oct 17;2:917201. doi: 10.3389/fmmed.2022.917201. eCollection 2022.
6
Basic implications on three pathways associated with SARS-CoV-2.与严重急性呼吸综合征冠状病毒2（SARS-CoV-2）相关的三条途径的基本影响。
Biomed J. 2025 Apr;48(2):100766. doi: 10.1016/j.bj.2024.100766. Epub 2024 Jul 14.
7
Toll-like receptors in health and disease.健康与疾病中的Toll样受体
MedComm (2020). 2024 Apr 29;5(5):e549. doi: 10.1002/mco2.549. eCollection 2024 May.
8
A comprehensive review on pharmacologic agents, immunotherapies and supportive therapeutics for COVID-19.关于COVID-19的药物制剂、免疫疗法和支持性疗法的全面综述。
Narra J. 2022 Dec;2(3):e92. doi: 10.52225/narra.v2i3.92. Epub 2022 Dec 8.
9
Identifying novel inhibitors targeting Exportin-1 for the potential treatment of COVID-19.鉴定针对 Exportin-1 的新型抑制剂，用于 COVID-19 的潜在治疗。
Arch Microbiol. 2024 Jan 19;206(2):69. doi: 10.1007/s00203-023-03761-z.
10
SARS-CoV-2 activates the TLR4/MyD88 pathway in human macrophages: A possible correlation with strong pro-inflammatory responses in severe COVID-19.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）激活人类巨噬细胞中的Toll样受体4（TLR4）/髓样分化因子88（MyD88）通路：与重症冠状病毒病2019（COVID-19）中强烈的促炎反应可能存在关联。
Heliyon. 2023 Nov 17;9(11):e21893. doi: 10.1016/j.heliyon.2023.e21893. eCollection 2023 Nov.
本文引用的文献
1
Clinical and biological data on the use of hydroxychloroquine against SARS-CoV-2 could support the role of the NLRP3 inflammasome in the pathogenesis of respiratory disease.关于使用羟氯喹治疗新型冠状病毒肺炎的临床和生物学数据，可能支持NLRP3炎性小体在呼吸道疾病发病机制中的作用。
J Med Virol. 2021 Jan;93(1):124-126. doi: 10.1002/jmv.26217. Epub 2020 Jul 6.
2
Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients.辅助免疫疗法治疗重症 COVID-19 患者。
Cell Rep Med. 2020 May 19;1(2):100016. doi: 10.1016/j.xcrm.2020.100016. Epub 2020 Apr 30.
3
In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs.基于 SARS-CoV-2 刺突糖蛋白与 ACE-2 受体同源物和人类 TLR 相互作用的比较特征的计算机研究。
J Med Virol. 2020 Oct;92(10):2105-2113. doi: 10.1002/jmv.25987. Epub 2020 May 17.
4
Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages.COVID-19 患者的病理性炎症：单核细胞和巨噬细胞的关键作用。
Nat Rev Immunol. 2020 Jun;20(6):355-362. doi: 10.1038/s41577-020-0331-4. Epub 2020 May 6.
5
Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2.针对新型冠状病毒 SARS-CoV-2 的基于肽的亚单位疫苗设计。
Microb Pathog. 2020 Aug;145:104236. doi: 10.1016/j.micpath.2020.104236. Epub 2020 May 4.
6
COVID-19: towards understanding of pathogenesis.新型冠状病毒肺炎：对发病机制的认识
Cell Res. 2020 May;30(5):367-369. doi: 10.1038/s41422-020-0327-4.
7
SARS-CoV-2 and viral sepsis: observations and hypotheses.SARS-CoV-2 与病毒败血症：观察与假说。
Lancet. 2020 May 9;395(10235):1517-1520. doi: 10.1016/S0140-6736(20)30920-X. Epub 2020 Apr 17.
8
Development of epitope-based peptide vaccine against novel coronavirus 2019 (SARS-COV-2): Immunoinformatics approach.基于表位的新型冠状病毒 2019（SARS-CoV-2）肽疫苗的研制：免疫信息学方法。
J Med Virol. 2020 Jun;92(6):618-631. doi: 10.1002/jmv.25736. Epub 2020 Mar 5.
9
Toll-like receptor polymorphism in host immune response to infectious diseases: A review. Toll 样受体多态性与宿主抗感染免疫反应：综述。
Scand J Immunol. 2019 Jul;90(1):e12771. doi: 10.1111/sji.12771. Epub 2019 May 20.
10
Toll-like receptors: promising therapeutic targets for inflammatory diseases. Toll 样受体：炎症性疾病有前景的治疗靶点。
Arch Pharm Res. 2016 Aug;39(8):1032-49. doi: 10.1007/s12272-016-0806-9. Epub 2016 Aug 11.
Zotero 插件